NeuroSense has announced new statistically significant results from the 12-month analysis of its PARADIGM phase 2b study, which assessed Primec for the treatment of patients with amyotrophic lateral sclerosis (ALS).

AstraZeneca has announced that the EC has approved Tagrisso (osimertinib), with the addition of pemetrexed and platinum-based chemotherapy, for the first-line treatment of adult patients with advanced epidermal growth factor receptor-mutated non-small cell lung cancer whose tumours have exon 19 deletions or exon 21 mutations.

Www.pharmatimes.com/croy

Oxolife has announced positive phase 2 clinical data on its fertility pill OXO-001 at the European Society of Human Reproduction and Embryology (ESHRE) 40th annual meeting, which was held in Amsterdam, the Netherlands.

Welcome to the july/august issue of pharmafocus!

Www.samedanltd.com

Pharmarole.com

Eisai and Biogen have announced that Leqembi (lecanemab) has been launched in China as a treatment for mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD dementia, following its approval in January 2024.

Evaluating the infected blood scandal and the outcomes of its inquiry

AbbVie has announced that the EMA's CHMP has granted a positive opinion to Tepkinly (epcoritamab), recommending the conditional marketing authorisation of the drug as a monotherapy treatment for adult patients with relapsed or refractory (r/r) follicular lymphoma (fl).

Eli Lilly has announced that it will donate $6.5m to the United States Fund for UNICEF in order to expand UNICEF's work to ‘improve the health outcomes of millions of children and youth at risk of noncommunicable diseases (NCDs) living in resource-limited settings in India’, according to the press release.

The FDA has granted an expanded orphan drug designation (ODD) for brain cancer immunotherapy survaxm, originally created at Roswell Park Comprehensive Cancer Center.